Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.

Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announces the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. With this transaction, Alfasigma adds Ocaliva to its portfolio, the only second-line treatment approved by the Food and Drug Administration (FDA) for primary biliary cholangitis (PBC), a progressive autoimmune disease affecting the liver. The deal will strengthen Alfasigma’s pipeline, with the addition of a novel fixed-dose combination possibly establishing a new treatment paradigm for PBC.

Read the full article: Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc. //

Source: https://www.businesswire.com/news/home/20231108637748/en/Alfasigma-completes-acquisition-of-Intercept-Pharmaceuticals-Inc.

Scroll to Top